#ASH22: Re­gen­eron re­veals its first PhII da­ta in con­test­ed CD20xC3 bis­pe­cif­ic race

NEW OR­LEANS — Re­gen­eron re­port­ed the first in­ter­im re­sults from a Phase II clin­i­cal tri­al of its bis­pe­cif­ic an­ti­body for cer­tain lym­phomas.

The phar­ma will need …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER